KV Pharmaceutical Pledges To Improve Finances, But NYSE Demands Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Already plagued by scandal, KV Pharma is subject to NYSE delisting if overdue 2009 annual report is not filed soon.